

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. **6303.000-US** (previously **452345/0007JJD/DLS**)

Serial No. 09/877,492

EB 17 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Aspe et al.

Filing Date June 8, 2001

Group 3713

C IFIN		U.S. PA	TENT DOCUMENTS	<del></del>			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
lunc	5,867,821	2/2/99	Ballantyne et al.	705	2		
rune	5,924,074	7/13/99	Evans	705	3		
UNC	5,940,802	3/17/99	Hildebrand et al.	705	3		
ime	5,954,641	9/21/99	Kehr et al.	600	3		
Mer	6,014,631	1/11/00	Teagarden et al.	705	3		
une	6,018,713	1/25/00	Coli et al.	705	2		
Mar	6,024,699	2/15/00	Surwit et al.	600	300		
un	6,076,166	6/13/00	Moshfeghi et al.	713_	201		
ine	6,085,752	7/11/00	Kehr et al.	128	897		
<b>Y</b>		FOREIGN	PATENT DOCUMENTS				_
	DOCUMENT					TRANSLATION	
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
						-	
							L,

Memo from Dr. Geoffrey, S. Gates of Mayo Clinic to Len Smith of Novo Nordisk®

Pharmaceuticals, Inc. received February 9, 2004

Information concerning the American Diabetes Association 60th Scientific Sessions, San

Antonio, June 9-13, 2000 and other materials provided by Stroock, Stroock and Lawan

Statement Concerning NovoTrack®/MayoTrack Presentations, Diabetes Monitors and

Diabetes Management Web Sites

John D. Piette, BioMed Central, Abstract, Enhancing Support via

Interactive Technologies

Nebel et al., Patient Education and Counseling, Vol. 46, Issue 1, pages 55-59 (2002)

"Evaluation of Canagurar Board interactive datasets education program..."

Nebel et al., Abstract, University of Leipzig, Germany

"Considertion of mayls for gotions of diabetes medication and computer and page of the considered of the program and patterns of the page of the considered of the considered of the page of the considered of the

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Aity. Docket No. 6303.000-US (previously 452345/0007JJD/DLS) Serial No. 09/877,492

FEB 17 2001

HINTORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Aspe et al.

Filing Date June 8, 2001

Group 3713

To 7158	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Thing Date & Circ O, 200		1 0.004 0.10						
		U.S. PA	TENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
W	6,102,855	8/15/00	Kehr et al.	600	300						
W	6,139,495	10/31/00	De La Huerga	600	300						
N	6,151,581	11/21/00	Kraftson et al.	705	3						
W	6,161,095	12/12/00	Brown	705	2						
me	6,168,563 B1	1/2/01	Brown	600	301						
·					<b>_</b>	<u> </u>					
		FOREIGN	PATENT DOCUMENTS			<del></del>					
	DOCUMENT					TRANSLATION					
	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO				
	-										
1	OTHER	OCTIMENTS (Inchr	ling Author, Title, Date, Pert	inent Pages, E	te.)						
	Press Releas	e, Area Malls k	Cick-Off Vismed Inte	ractive He	alth Kiosks,						
you	www.touchv	www.touchvision.com/pr/marion.htm (2002)									
<u> </u>	Press Releas	Press Release, Novo Nordisk® Launches Interactive Diabetes Management Website									
VIN VIN		www.findarticles.com (2001)									
	Diabetes In	Control.com, Is	sue 117, item 2 (200	2)							
put put											
· , ,	Gates et al.,	Gates et al., International Diabetes Monitor, Vol. 15, No. 3, pages 1-6 (2003)									
m											
.1	Smith et al.,	Smith et al., Diabetes Care, Vol. 21, No. 6, pages 972-976 (1998)									
m											
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Montori et a	Montori et al., Diabetes Care, Vol. 25, No. 11, pages 1952-1957 (2002)									
Min											
EVAMINER / //	lan M. Christman		DATE CONSIDERE	08 7	4 104						

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPRP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.